双打击淋巴瘤患者达到首次完全缓解后的结局
研究纳入完成一线R-CHOP或强化治疗后达到首次完全缓解且适合自体干细胞移植的双打击淋巴瘤患者159例,以一线治疗结束后3个月为landmark分析起点。全组3年无复发生存率和总生存率分别为80%和87%,自体移植组与非移植组无显著差异,但接受R-CHOP者3年无复发生存率低于强化治疗者(56%对88%,P=0.002)。
要点
- 全组159例达首次完全缓解的双打击淋巴瘤患者3年无复发生存率80%、总生存率87%。
- 自体移植组62例与非移植组97例的3年无复发生存率和总生存率无显著差异。
- R-CHOP组3年无复发生存率低于强化治疗组(56%对88%,P=0.002)。
核心结论
- 在目前已知最大系列中,巩固性自体干细胞移植与3年无复发生存率或总生存率改善无关。
- 接受R-CHOP治疗的患者3年无复发生存率低于接受强化一线治疗者。
- 结合新诊断双打击淋巴瘤对R-CHOP反应率低于强化一线治疗的报道,本研究发现进一步支持对该患者人群使用强化一线治疗。
研究设计与样本
- 纳入完成一线R-CHOP或强化一线治疗后达到首次完全缓解且被评定为适合自体干细胞移植的双打击淋巴瘤患者。
- 采用landmark分析,时间零点定义为一线治疗结束后3个月。
- 在一线治疗结束前或至该时间点未随访到的复发患者被排除。
主要发现
- 全部患者(n=159)3年无复发生存率和总生存率分别为80%和87%。
- 自体干细胞移植组(n=62)与非移植组(n=97)的3年无复发生存率和总生存率无显著差异。
- 接受R-CHOP者与接受强化治疗者的3年无复发生存率分别为56%和88%(P=0.002),R-CHOP组较低。
- 在R-CHOP或强化治疗队列中按是否接受自体干细胞移植分析,3年无复发生存率和总生存率均无显著差异。
- 复发后中位总生存期为8.6个月。
关键数值与推荐
- 全部患者(n=159)3年无复发生存率80%、总生存率87%。
- 自体干细胞移植组(n=62)与非移植组(n=97)3年无复发生存率和总生存率无显著差异。
- R-CHOP组与强化治疗组3年无复发生存率分别为56%和88%(P=0.002)。
- 复发后中位总生存期8.6个月。
临床怎么用
- 作者认为,结合新诊断双打击淋巴瘤对R-CHOP反应率低于强化一线治疗的报道,本研究发现进一步支持对该患者人群使用强化一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy is unclear. Methods Patients with DHL who achieved first complete remission following completion of front-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and deemed fit for autoSCT, were included. A landmark analysis was performed, with time zero defined as 3 months after completion of front-line therapy. Patients who experienced relapse before or who were not followed until that time were excluded. Results Relapse-free survival (RFS) and overall survival (OS) rates at 3 years were 80% and 87%, respectively, for all patients (n = 159). Three-year RFS and OS rates did not differ significantly for autoSCT (n = 62) versus non-autoSCT patients (n = 97), but 3-year RFS was inferior in patients who received R-CHOP compared with intensive therapy (56% v 88%; P = .002). Three-year RFS and OS did not differ significantly for patients in the R-CHOP or intensive therapy cohorts when analyzed by receipt of autoSCT. The median OS following relapse was 8.6 months. Conclusion In the largest reported series, to our knowledge, of patients with DHL to achieve first complete remission, consolidative autoSCT was not associated with improved 3-year RFS or OS. In addition, patients treated with R-CHOP experienced inferior 3-year RFS compared with those who received intensive front-line therapy. When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population.
引用
- Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017. PMID: 28475457. doi:10.1200/JCO.2017.72.2157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。